Specialty Outpatient Facilities fairness opinions
7 public-company healthcare transactions in Specialty Outpatient Facilities, 2010-2025, each with the banker's fairness opinion from the SEC filing: the DCF discount rate and terminal assumptions, the selected companies and precedent transactions, and the deal terms.
Valuation benchmarks
Specialty Outpatient Facilities transactions with a fairness opinion, 2010-2025. Multiples are enterprise value over the last-twelve-months figure disclosed in the filing; the discount rate is the midpoint of the range the banker used in its DCF.
Bankers most often engaged in Specialty Outpatient Facilities
Marshall & Stevens (1) · Lazard (1) · J.P. Morgan (1) · Evercore (1) · William Blair (1) · Lazard Middle Market (1) · Dresner Partners (1)
All Specialty Outpatient Facilities transactions
| Announced | Target | Acquirer | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | FONAR | Damadian family Acquisition Group | $69.3M | 4.3x | 0.65x | 14.5% | Marshall & Stevens |
| 2017-04-11 | Alliance Healthcare Services | Tahoe Investment Group Co. | $683M | 5.7x | 1.33x | 9.0%–10.0% | Lazard |
| 2017-01-09 | Surgical Care Affiliates | Optum | $3.3B | 16.4x | 2.75x | 6.5%–7.5% | J.P. Morgan |
| 2016-06-15 | AmSurg | Envision Healthcare Holdings | $7.1B | 12.0x | 2.29x | 6.3%–7.2% | Evercore |
| 2011-01-21 | NovaMed | Surgery Partners | $214M | 7.8x | 1.41x | 12.0%–16.0% | William Blair |
| 2010-05-06 | HealthTronics | Endo Health Solutions | $315M | 8.7x | 1.48x | 11.5%–13.5% | Lazard Middle Market |
| 2010-04-14 | Dialysis Corporation of America | U.S. Renal Care | $112M | 14.1x | 1.13x | 12.0%–16.0% | Dresner Partners |